Odyssey Therapeutics IPO raises $315m as OD-001 hits UC proof-of-concept
Odyssey Therapeutics debuted on the Nasdaq Capital Market in May 2026 under the ticker ODTX, raising gross proceeds of $314.8 million through an initial public offering and a concurrent private placement. Combined with cash already on hand, the company reports a pro-forma cash position of $464.4 million, which it expects to fund operations into the second half of 2028.
The IPO priced at $18.00 per share, with 15.5 million shares sold in the public offering and a further 1.39 million shares placed concurrently. Underwriters partially exercised an overallotment option, adding 600,000 additional shares at the same price. The company recorded a net loss of $38.3 million for the first quarter of 2026, broadly flat versus the $38.4 million loss in the same period a year earlier. Research and development expenditure fell to $32.3 million from $38.8 million, a movement the company attributed primarily to a non-cash lease impairment charge recorded in the prior-year quarter rather than a reduction in underlying spend.
OD-001 Phase 2a results
The headline clinical news accompanying the financial report is proof-of-concept data for OD-001, Odyssey's oral small-molecule RIPK2 scaffolding inhibitor in moderate to severe ulcerative colitis. Forty-nine patients completed 12 weeks of treatment in the Phase 2a monotherapy signal-seeking trial. The company reported that 27% of patients achieved clinical remission and 61% achieved clinical response, with the drug showing tolerability at both doses tested. Odyssey says the candidate performed across both therapy-naive patients and those previously exposed to advanced therapies, a patient segment typically considered harder to treat.
Gary D. Glick, President and Chief Executive Officer, said the results demonstrate the company's aim of "breaking the therapeutic ceiling in inflammatory bowel disease and providing a safe, oral medicine for long-term disease management." Odyssey plans to initiate both a Phase 2b monotherapy trial and a Phase 2a combination trial pairing OD-001 with the gut-selective integrin inhibitor vedolizumab in the second half of 2026, with topline induction data from both studies targeted for the second half of 2027.
The company's second clinical programme, OD-002, targets SLC15A4, a lysosomal transporter with a proposed role in innate immune signalling. Odyssey aims to file a clinical trial application in the second half of 2026, which would permit a Phase 1/2a study in healthy participants and patients to begin in the first half of 2027.
Market context
The inflammatory bowel disease therapeutics market is one of the most competitive in immunology, with established biologics including anti-TNF agents, anti-integrin therapies and IL-12/23 inhibitors already on-market, and a growing cluster of oral small-molecule candidates, notably JAK inhibitors such as tofacitinib and upadacitinib, occupying an increasingly prominent position. The RIPK2 pathway is a less-trafficked mechanism, and if Odyssey can replicate Phase 2a signals in larger trials, the oral and potentially combination-friendly profile of OD-001 could differentiate it from the current JAK-inhibitor class, which carries a black-box warning for serious cardiovascular and thrombotic events in some populations.
Remission rates of 27% at 12 weeks in a signal-seeking monotherapy study are of interest, though cross-trial comparisons are fraught given differing patient selection criteria, baseline disease severity, and endpoint definitions. Full results from the Phase 2a study are expected to be presented at a scientific conference in the second half of 2026, which will give clinicians and investors their first opportunity to interrogate the underlying dataset, including safety, endoscopic findings and subgroup breakdowns. The two upcoming trials, if initiated on schedule, will determine whether the early signal survives in a more rigorous efficacy design.